3-Amino-4-fluorobenzoic acid | CAS:2365-85-7

We serve 3-Amino-4-fluorobenzoic acid CAS:2365-85-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Amino-4-fluorobenzoic acid

Chemical Name:3-Amino-4-fluorobenzoic acid
CAS.NO:2365-85-7
Synonyms:3-Amino-4-fluorobenzoic acid
5-Carboxy-2-fluoroaniline
ethyl 4-fluoro-3-aminobenzoate
4-fluoro-3-aminobenzoic acid
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 335.5±27.0 °C at 760 mmHg
Melting Point 184 °C
Molecular Formula C7H6FNO2
Molecular Weight 155.126
Flash Point 156.7±23.7 °C
Vapour Pressure 0.0±0.8 mmHg at 25°C
Index of Refraction 1.606
 
Specification:
Appearance:White to light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 3-Amino-4-fluorobenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-fluoro-3-aminobenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 4-fluoro-3-aminobenzoate Use and application,4-fluoro-3-aminobenzoic acid technical grade,usp/ep/jp grade.


Related News: Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).2-(4-Methyl-2-phenyl-1-piperazinyl)-3-pyridinemethanol manufacturer The fine and functional chemicals sector provides new growth drivers.Diethoxydimethylsilane supplier Any drug or medication is composed of two components.L-Tryptophan vendor It is foreseeable that in the future, the capacity and output of bulk APIs in China will decrease, the supply-demand relationship will be balanced, and prices and profits will gradually return to a more reasonable range. The era of low prices in the past will be gone forever. Individual APIs Varieties may even lose their price competitive advantage and move abroad.A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA’s concerns.